ALNYLAM PHARMACEUTICALS, INC. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

ALNYLAM PHARMACEUTICALS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $3.71 billion for the year ending 2025.

  • ALNYLAM PHARMACEUTICALS, INC. showed an increase of +65.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from ALNYLAM PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 12, 2026.
  • XBRL data for this metric is available from 2016 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 11 years of available data (2016 to 2025), ALNYLAM PHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 7,775.4%.
  • Historical annual values: Fiscal year 2025: $3.71 billion | Fiscal year 2024: $2.25 billion | Fiscal year 2023: $1.83 billion | Fiscal year 2022: $1.04 billion | Fiscal year 2021: $844.29 million | Fiscal year 2020: $492.85 million | Fiscal year 2019: $219.75 million | Fiscal year 2018: $74.91 million | Fiscal year 2017: $2.90 million | Fiscal year 2017: $89.91 million | Fiscal year 2016: $47.16 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: